Australian Schizophrenia Care and Assessment Programme: Real-world schizophrenia: Economics

Australian and New Zealand Journal of Psychiatry

Volumn 41, Issue 10, 2007, Pages 819-829

  Fitzgerald, Paul B ^a   Montgomery, William ^b   de Castella, Anthony R ^a   Filia, Kate M ^a   Filia, Sacha L ^a   Christova, Laura ^c   Jackson, Dan ^c   Kulkarni, Jayashri ^a  

^a MONASH UNIVERSITY   (Australia)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c M TAG A Unit of IMS Health   (Australia)

Author keywords

Antipsychotic agents; Health care costs; Outcomes research; Psychosocial aspects; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUSTRALIA; COHORT ANALYSIS; COST CONTROL; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EMPLOYMENT STATUS; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH PROGRAM; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT INFORMATION; PROSPECTIVE STUDY; QUALITY OF LIFE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; AUSTRALIA; COMMUNITY MENTAL HEALTH SERVICES; COST OF ILLNESS; EMPLOYMENT; FEMALE; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; OUTPATIENTS; SCHIZOPHRENIA; TRANSPORTATION;

EID: 34548648842     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670701579025     Document Type: Article

References (38)

1. COAG (2006) COAG, COAG, Canberra
2. Andrews, G. (2006) It would be cost-effective to treat more people with mental disorders. Aust N Z J Psychiatry, 40, pp. 613-615.
3. Knapp, M. (1997) Costs of schizophrenia. Br J Psychiatry, 171, pp. 509-518.
4. Knapp, M. (2000) Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl, 102, pp. 15-18.
5. Knapp, M., Mangalore, R. and Simon, J. (2004) The global costs of schizophrenia. Schizophr Bull, 30, pp. 279-293.
6. Berk, ML and Monheit, AC. (2001) The concentration of health care expenditures, revisited. Health Aff (Millwood), 20, pp. 9-18.
7. Jablensky, AV, McGrath, J. and Herrman, H. (1999) People living with psychotic illness: An Australian study 1997-98, Commonwealth of Australia, Canberra
8. Murray, CL and Lopez, AD. (1996) The global burden of disease, Harvard University Press, Cambridge, MA
9. Mathers, C., Vos, T. and Stevenson, C. (1999) The burden of disease and injury in Australia, Australian Institute of Health and Welfare, Canberra
10. Begg, S., Vos, T., Barker, B., Stevenson, C., Stanley, L. and Lopez, A. (2003) The burden of disease and injury in Australia, p. 2007. AIHW, Canberra
11. Andrews, G., Issakidis, C., Sanderson, K., Corry, J. and Lapsley, H. (2004) Utilising survey data to inform public policy: Comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry, 184, pp. 526-533.
12. Hall, W., Goldstein, G., Andrews, G., Lapsley, H., Bartels, R. and Silove, D. (1985) Estimating the economic costs of schizophrenia. Schizophr Bull, 11, pp. 598-610.
13. Andrews, G. (1991) The cost of schizophrenia revisited. Schizophr Bull, 17, pp. 389-394.
14. Langley-Hawthorne, C. (1997) Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther, 19, pp. 1470-1495.
15. Carr, VJ, Neil, AL, Halpin, SA, Holmes, S. and Lewin, TJ. (2003) Costs of schizophrenia and other psychoses in urban Australia: Findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry, 37, pp. 31-40.
16. Mathers, CD, Vos, ET, Stevenson, CE and Begg, SJ. (2000) The Australian Burden of Disease Study: Measuring the loss of health from diseases, injuries and risk factors. Med J Aust, 172, pp. 592-596.
17. Mathers, CD, Vos, ET, Stevenson, CE and Begg, SJ. (2001) The burden of disease and injury in Australia. Bull World Health Organ, 79, pp. 1076-1084.
18. Vos, T., Mathers, C. and Herrman, H. (2001) The burden of mental disorders in Victoria, 1996. Soc Psychiatry Psychiatr Epidemiol, 36, pp. 53-62.
19. Dewa, CS, Remington, G., Herrmann, N., Fearnley, J. and Goering, P. (2002) How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther, 24, pp. 1466-1476.
20. Crown, WH, Neslusan, C., Russo, PA, Holzer, S., Ozminkowski, R. and Croghan, T. (2001) Hospitalization and total medical costs for privately insured persons with schizophrenia. Adm Policy Ment Health, 28, pp. 335-351.
21. Svarstad, BL, Shireman, TI and Sweeney, JK. (2001) Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv, 52, pp. 805-811.
22. Lewis, M., McCrone, P. and Frangou, S. (2001) Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry, 62, pp. 749-756.
23. Haro, JM, Edgell, ET and Jones, PB (2003) The European Schizophrenia Outpatient Health Outcomes (SOHO) study: Rationale, methods and recruitment. Acta Psychiatr Scand, 107, pp. 222-232.
24. Thornicroft, G., Leese, M. and Tansella, M. (2002) Gender differences in living with schizophrenia. A cross-sectional European multi-site study. Schizophr Res, 57, pp. 191-200.
25. Sytema, S. and Burgess, P. (1999) Continuity of care and readmission in two service systems: A comparative Victorian and Groningen case-register study. Acta Psychiatr Scand, 100, pp. 212-219.
26. Harvey, CA and Fielding, JM. (2003) The configuration of mental health services to facilitate care for people with schizophrenia. Med J Aust, 178, p. S49.
27. Mond, J., Morice, R., Owen, C. and Korten, A. (2003) Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry, 37, pp. 55-61.
28. Ascher-Svanum, H., Faries, D., Zhu, B., Ernst, F., Swartz, M. and Swanson, J. (2006) Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry, 67, pp. 453-460.
29. Burns, T., Christova, L. and Cooper, S. (2006) Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: A naturalistic cohort study. Acta Psychiatr Scand, 113, pp. 126-134.
30. Kulkarni, J., De Castella, AR and Filia, KM (2006) The Australian SCAP study: Real-world scOizophrenia: outcomes. Aust N Z J Psychiatry
31. Australian Government Department of Health and Ageing. Australian Government Department of Health and Ageing, Australian Government Department of Health and Ageing, Canberra
32. Carr, V., Neil, A., Halpin, S. and Holmes, S. (2002) Costs of psychosis in urban Australia, Australian Government Department of Health and Ageing, Canberra
33. Liljas, B. (1998) How to calculate indirect costs in economic evaluations. Pharmacoeconomics, 13, pp. 1-7.
34. Lehman, AF, Fischer, EP and Postrado, L. (2003) The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care. Schizophr Bull, 29, pp. 247-256.
35. Carr, VJ, Lewin, TJ, Neil, AL, Halpin, SA and Holmes, S. (2004) Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. Br J Psychiatry, 184, pp. 517-525.
36. Michie, PT, Budd, TW and Todd, J. (2000) Duration and frequency mismatch negativity in schizophrenia. Clin Neurophysiol, 111, pp. 1054-1065.
37. Access Economics (2002) An analysis of the burden of schizophrenia and related suicide in Australia.
38. Steinwachs, DM, Kasper, JD and Skinner, EA. (1992) Patterns of use and costs among severely mentally ill people. Health Aff (Millwood), 11, pp. 178-185.